What one share of Accustem Sciences holds
We are a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people worldwide who are diagnosed with cancer each year.
Accustem Sciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.10 |
|---|---|
| Cash and investments | $0.00 |
| Book value | −$0.26 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$0.07 | — | — | — | $0.07 |
| 2022 | — | −$0.34 | $0.00 | −$0.16 | — | −$0.01 |
| 2023 | — | −$0.18 | — | — | — | −$0.19 |
| 2024 | — | −$0.13 | — | — | — | −$0.27 |
| 2025 | — | −$0.12 | — | — | — | −$0.21 |
Common questions about Accustem Sciences
How much does one share of Accustem Sciences earn?
Over the last 12 months, Accustem Sciences lost $0.10 for each share.
Does Accustem Sciences pay a dividend?
Accustem Sciences didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Accustem Sciences’s book value per share?
Accustem Sciences’s book value is negative (−$0.26 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Accustem Sciences have?
Each share of Accustem Sciences has $0.00 of cash and investments, as of June 30, 2026.
Has Accustem Sciences bought back shares?
Accustem Sciences’s share count rose about 52% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.